Therefore, future studies on a larger and more comprehensively annotated patient cohort are crucial to validate our findings and determine whether NAT10 expression correlates with specific clinical pathological features (e.g., tumor grade, stage, or molecular subtype). This evidence concerns the gene NAT10 and neoplasm.